Delcath Systems Announces Presentation of CHOPIN Phase 2 Trial Results at ESMO 2025 Congress for Metastatic Uveal Melanoma Treatment
Reuters
Sep 23, 2025
<a href="https://laohu8.com/S/DCTH">Delcath Systems</a> Announces Presentation of CHOPIN Phase 2 Trial Results at ESMO 2025 Congress for Metastatic Uveal Melanoma Treatment
Delcath Systems, Inc., a company specializing in interventional oncology for liver cancers, has announced the acceptance of an oral presentation at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. The presentation will cover results from the CHOPIN Phase 2 trial, which is an investigator-initiated study evaluating the safety, tolerability, and efficacy of combining systemic ipilimumab and nivolumab with Delcath's CHEMOSAT® Hepatic Delivery System. The study focuses on patients with metastatic uveal melanoma. Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center, will present the findings on October 18, 2025. The presentation's abstract is numbered LBA59 and will be featured in the session titled "Melanoma and other skin tumours." Further details will become available on Delcath's website after the ESMO embargo is lifted on the presentation date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922014721) on September 22, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.